ATE222889T1 - Hydroxamsäure-derivate - Google Patents

Hydroxamsäure-derivate

Info

Publication number
ATE222889T1
ATE222889T1 AT98915209T AT98915209T ATE222889T1 AT E222889 T1 ATE222889 T1 AT E222889T1 AT 98915209 T AT98915209 T AT 98915209T AT 98915209 T AT98915209 T AT 98915209T AT E222889 T1 ATE222889 T1 AT E222889T1
Authority
AT
Austria
Prior art keywords
hydroxamic acid
acid derivatives
derivatives
treat
inhibit
Prior art date
Application number
AT98915209T
Other languages
English (en)
Inventor
Paul F Jackson
Kevin L Tays
Keith M Maclin
Barbara S Slusher
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Application granted granted Critical
Publication of ATE222889T1 publication Critical patent/ATE222889T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98915209T 1997-04-04 1998-04-02 Hydroxamsäure-derivate ATE222889T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/825,997 US5962521A (en) 1997-04-04 1997-04-04 Hydroxamic acid derivatives
PCT/US1998/006382 WO1998045256A1 (en) 1997-04-04 1998-04-02 Hydroxamic acid derivatives

Publications (1)

Publication Number Publication Date
ATE222889T1 true ATE222889T1 (de) 2002-09-15

Family

ID=25245426

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98915209T ATE222889T1 (de) 1997-04-04 1998-04-02 Hydroxamsäure-derivate

Country Status (8)

Country Link
US (3) US5962521A (de)
EP (1) EP0973731B1 (de)
JP (1) JP2001519809A (de)
AT (1) ATE222889T1 (de)
AU (1) AU742418B2 (de)
CA (1) CA2285906A1 (de)
DE (1) DE69807455D1 (de)
WO (1) WO1998045256A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7070782B1 (en) * 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US7037647B1 (en) 1995-02-24 2006-05-02 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US20040253246A1 (en) * 1996-02-23 2004-12-16 Israeli Ron S. Prostate-specific membrane antigen and uses thereof
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US6395718B1 (en) * 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
AU773915B2 (en) 1999-04-28 2004-06-10 Georgetown University Ligands for metabotropic glutamate receptors
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
US6228888B1 (en) 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
CA2380820A1 (en) * 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Neurotherapeutic clavulanate composition and method
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
US6348464B1 (en) 1999-11-12 2002-02-19 Guilford Pharmaceuticals, Inc. Pyrrolecarbonylimino derivatives as naaladase inhibitors
AU2001265111A1 (en) * 2000-05-30 2001-12-11 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
MXPA02011921A (es) 2000-05-30 2003-04-22 Guilford Pharm Inc Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
US20020013295A1 (en) * 2000-05-30 2002-01-31 Slusher Barbara S. Naaladase inhibitors for treating amyotrophic lateral sclerosis
IT1318636B1 (it) * 2000-07-21 2003-08-27 Roberto Pellicciari Derivati dell'acido 2- o 3- tenoico ad attivita' antagonista deirecettori del glutammato.
EP1363920B1 (de) 2001-02-07 2006-08-23 Beth Israel Deaconess Medical Center Modifizierte psma-liganden und deren verwendung
EP1372551B1 (de) * 2001-03-08 2008-09-17 The Trustees Of The University Of Pennsylvania Faciale amphiphile polymere als antiinfektiöse mittel
AU2002256505B2 (en) * 2001-05-11 2008-06-26 Eisai Inc. Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
US7148250B2 (en) * 2001-12-28 2006-12-12 Guilford Pharmaceuticals Inc. Indoles as NAALADase inhibitors
PT1472541E (pt) 2002-01-10 2009-12-21 Univ Johns Hopkins Agentes de imagiologia e métodos de imagiologia de naaladase de psma
US20040072815A1 (en) * 2002-02-12 2004-04-15 Koppel Gary A. Antibiotic composition and method
AU2003220222A1 (en) 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
DE602004021476D1 (de) * 2003-03-03 2009-07-23 Eisai Corp North America THIOLACTONE ALS NAALADase INHIBITOREN
EP2471526A3 (de) * 2003-03-17 2012-12-12 The Trustees Of The University Of Pennsylvania Fazial-amphiphile Polymere und Oligomere sowie Verwendungen davon
EP1711455A4 (de) 2004-01-23 2007-11-07 Univ Pennsylvania Fazial amphiphile polyaryl- und polyarylalkinylpolymere und -oligomere und deren anwendungen
US8221804B2 (en) 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
JP2008531585A (ja) * 2005-02-25 2008-08-14 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 表面が両親媒性のポリマーおよびオリゴマー、それらの組成物そして癌治療方法におけるそれらの使用
EP4023624A1 (de) 2006-11-08 2022-07-06 Molecular Insight Pharmaceuticals, Inc. Heterodimere von glutaminsäure
ES2768224T3 (es) 2007-08-17 2020-06-22 Purdue Research Foundation Conjugados ligando-enlazador de unión a PSMA y métodos para su uso
WO2009132051A1 (en) 2008-04-21 2009-10-29 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
EP2706057B1 (de) 2008-12-05 2016-04-20 Molecular Insight Pharmaceuticals, Inc. Bis(imidazolyl)verbindungen and Radionuclidkomplexe
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
AU2010328230B2 (en) 2009-12-07 2016-06-02 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
IN2012DN05025A (de) * 2009-12-07 2015-10-23 Univ Johns Hopkins
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2800471A4 (de) 2012-01-06 2015-11-04 Molecular Insight Pharm Inc Metallkomplexe von poly(carboxyl)aminhaltigen liganden mit einer affinität für carboanhydrase ix
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
EP3300746B1 (de) 2013-01-14 2019-05-15 Molecular Insight Pharmaceuticals, Inc. Radiopharmazeutika auf triazinbasis und strahlungsabbildungsmittel
CA2924360C (en) 2013-10-18 2022-04-26 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA2930581A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP4046989A1 (de) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selektive histondeacetylaseinhibitoren zur behandlung von menschlichen erkrankungen
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3737376B1 (de) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Selektive histondeacetylaseinhibitoren zur behandlung von menschlichen erkrankungen

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151172A (en) * 1977-08-11 1979-04-24 E. R. Squibb & Sons, Inc. Phosphonoacyl prolines and related compounds
US4316896A (en) * 1978-09-07 1982-02-23 Merck & Co., Inc. Aminoacid derivatives as antihypertensives
US4168267A (en) * 1978-10-23 1979-09-18 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl prolines
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4374131A (en) * 1981-04-27 1983-02-15 E. R. Squibb & Sons, Inc. Amino and substituted amino phosphinyl-alkanoyl compounds
US4555506A (en) * 1981-12-24 1985-11-26 E. R. Squibb & Sons, Inc. Phosphorus containing compounds and use as hypotensives
US4716155A (en) * 1981-12-24 1987-12-29 E. R. Squibb & Sons, Inc. Phosphorus containing compounds and hypotensive use thereof
US5156840A (en) * 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4950738A (en) * 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US5162512A (en) * 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
US4452791A (en) * 1982-03-15 1984-06-05 E. R. Squibb & Sons, Inc. Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4560680A (en) * 1982-03-15 1985-12-24 E. R. Squibb & Sons, Inc. Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4448772A (en) * 1982-04-22 1984-05-15 E. R. Squibb & Sons, Inc. Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension
US4560681A (en) * 1982-04-22 1985-12-24 E. R. Squibb & Sons, Inc. Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension
US4468519A (en) * 1982-06-14 1984-08-28 E. R. Squibb & Sons, Inc. Esters of phosphinylalkanoyl substituted prolines
US4703043A (en) * 1982-06-23 1987-10-27 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive
US4452790A (en) * 1982-06-23 1984-06-05 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
US4616005A (en) * 1982-06-23 1986-10-07 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
US4444765A (en) * 1982-07-14 1984-04-24 E. R. Squibb & Sons, Inc. Amino and substituted amino phosphinylalkanoyl compounds useful for treating hypertension
US4567166A (en) * 1982-07-14 1986-01-28 E. R. Squibb & Sons, Inc. Amino and substituted amino phosphinylalkanoyl compounds useful for treating hypertension
US4547324A (en) * 1982-07-29 1985-10-15 Stauffer Chemical Company Method for preparation of N-phosphonomethylglycine
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
FR2590674B1 (fr) * 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
US5190976A (en) * 1986-07-10 1993-03-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5093525A (en) * 1986-07-10 1992-03-03 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US4906779A (en) * 1986-07-10 1990-03-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5143908A (en) * 1986-11-05 1992-09-01 Merck & Co., Inc. Antibacterial agents and potentiators of carbapenem antibiotics
US4715994A (en) * 1986-11-05 1987-12-29 Merck & Co., Inc. Novel antibacterial agents and potentiators of carbapenem antibiotics
US5099063A (en) * 1986-11-05 1992-03-24 Merck & Co., Inc. Certain phosphinic acid derivatives having antibacterial activity
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
CA1305177C (en) * 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US5041644A (en) * 1987-07-06 1991-08-20 Merck & Co., Inc. Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid
JPS6413097A (en) * 1987-07-06 1989-01-17 Mitsubishi Chem Ind Phosphonic acid derivative
US4849525A (en) * 1987-09-21 1989-07-18 E. R. Squibb & Sons, Inc. Phosphinylcycloalkylcarbonyl and phosphinylcycloalkenylcarbonyl dipeptides
US4918064A (en) * 1987-10-21 1990-04-17 G. D. Searle & Co. Phenyl glycines for use in reducing neurotoxic injury
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
US4937183A (en) * 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
US5047227A (en) * 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
US5030732A (en) * 1988-03-03 1991-07-09 Merck & Co., Inc. Aminoethylphosphinic acid derivatives
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US4966999A (en) * 1988-06-07 1990-10-30 Cytogen Corporation Radiohalogenated compounds for site specific labeling
DE68925240T2 (de) * 1988-06-23 1996-06-13 Banyu Pharma Co Ltd Phosphinsäure-Derivate
US5147867A (en) * 1988-10-28 1992-09-15 Merck & Co., Inc. Phosphorus containing enzyme inhibitors
US4962097A (en) * 1988-10-28 1990-10-09 Merck & Co., Inc. Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors
US5145990A (en) * 1988-10-28 1992-09-08 Merck & Co., Inc. Phosphorous containing dhp enzyme inhibitors
US5196510A (en) * 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
US4994446A (en) * 1989-01-03 1991-02-19 Ramot - University Authority For Applied Research And Industrial Development Ltd. Drug system
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds
US5262568A (en) * 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5336689A (en) * 1990-03-02 1994-08-09 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5594007A (en) * 1991-04-18 1997-01-14 Pfizer Inc. Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols
JP2632754B2 (ja) * 1991-05-21 1997-07-23 塩野義製薬株式会社 脳内グルタミン酸遊離抑制剤
DE4141928A1 (de) * 1991-12-19 1993-06-24 Boehringer Mannheim Gmbh Neue phosphonobernsteinsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5326856A (en) * 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
AU4267293A (en) * 1992-05-01 1993-11-29 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
DE69334071T2 (de) 1992-11-05 2007-10-25 Sloan-Kettering Institute For Cancer Research Prostata-spezifisches membranantigen
US5449761A (en) * 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
US5495042A (en) * 1993-11-04 1996-02-27 Cytogen Corporation Non-alkaline purification of aminophosphonic acids
US5500420A (en) 1993-12-20 1996-03-19 Cornell Research Foundation, Inc. Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia
US5508273A (en) * 1993-12-30 1996-04-16 Ortho Pharmaceutical Corporation Substituted phosphonic acids and derivatives useful in treating bone wasting diseases
US7037647B1 (en) 1995-02-24 2006-05-02 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5804602A (en) 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
ID18382A (id) * 1996-09-27 1998-04-02 Guilford Pharm Inc Komposisi sediaan farmasi dan metoda pengobatan gangguan kompulsif dengan menggunakan inhibitor naaladase

Also Published As

Publication number Publication date
JP2001519809A (ja) 2001-10-23
AU742418B2 (en) 2002-01-03
CA2285906A1 (en) 1998-10-15
AU6945198A (en) 1998-10-30
WO1998045256A1 (en) 1998-10-15
US6271245B1 (en) 2001-08-07
US5962521A (en) 1999-10-05
EP0973731A1 (de) 2000-01-26
DE69807455D1 (de) 2002-10-02
EP0973731B1 (de) 2002-08-28
US20010044459A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
ATE222889T1 (de) Hydroxamsäure-derivate
DE69903618T2 (de) Phosphinsäure-derivate
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
ES2154253T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas.
ATE283848T1 (de) Thiarylsulfonamid-hydroxamsäurederivate
NO990543D0 (no) Hydroksam-og karboksylsyre-derivater med MMP- og TNF-inhiberingsaktivitet
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
BR9611479A (pt) Acidos alfa-iminoidroxâmicos e carboxílicos N-substituídos cíclicos e heterocíclicos
NO985652L (no) Anvendelse av naaladaseinhibitorer ved behandling av kreft
NO20010052D0 (no) NAALADase inhibitorer anvendbare som farmasöytiske forbindelser og preparater
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
DK0696456T3 (da) Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme
BR9911094A (pt) Composições e métodos para o tratamento detosse
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
TR199802638T2 (xx) Kanser tedavisinde naaladase inhibit�rleri kullan�m�.
BR9607541A (pt) Tratamento de doenças que tem por causa o fator de crescimento da citoquina
ES2177324T3 (es) Preparaciones de insulina destinadas a la entrega pulmonar y que contiene mentol.
NO20003888L (no) Anti-enzympreparater omfattende etylendiamindiravsyre
DK1231908T3 (da) Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf
AU2002211577A1 (en) Protecting therapeutic compositions from host-mediated inactivation
WO1999050671A3 (en) Toso as a target for drug screening
DK0819136T3 (da) Derivater og konjugater af MDP, som har en aktivitet, der stimulerer den hematopoietiske funktion, og præparat indeholdende disse
DE69821228T2 (de) Selektive mmp inhibitoren mit verringerten nebenwirkungen
NO980175L (no) Anvendelse av kationiske biopolymerer for å fremstille antiflassmidler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties